Literature DB >> 18753943

Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.

Laura Schirosi1, Sylvie Lantuejoul, Alberto Cavazza, Bruno Murer, Pierre Yves Brichon, Mario Migaldi, Giuliana Sartori, Alessandro Sgambato, Giulio Rossi.   

Abstract

Pleuro-pulmonary solitary fibrous tumor (SFT) is a relatively uncommon mesenchymal neoplasm of uncertain histogenesis, unknown molecular features, and unpredictable clinical behavior. Although complete resection is universally accepted as the most important single prognostic factor, some clinicopathologic characteristics (gross appearance, tumor size, mitotic index, tumor necrosis, hypercellularity, and pleomorphism) are related to patient outcome, and a staging system based on these parameters with practical therapeutical implications has been recently proposed by de Perrot et al. Here, 88 pleuro-pulmonary SFTs were collected and clinicopathologic characteristics including de Perrot classification, patients' follow-up, p53 expression, and several "targetable" kinases [c-kit, v-raf murine sarcoma viral oncogene homolog B1, platelet-derived growth factor receptor (PDGFR)-alpha/beta, c-met, epidermal growth factor receptor (EGFR)] were retrospectively analyzed. Fifty-two cases (59%) had at least 1 clinicopathologic feature related to malignancy, whereas mortality and recurrences occurred in 10.2% and 18.2% of the cases, respectively. de Perrot staging and high p53 expression were significantly related to the conventional clinicopathologic prognostic features as well as to overall survival (OS) and disease-free survival (DFS) (P<0.001). At multivariate analysis, high p53 expression and tumor necrosis were the only parameters significantly associated with OS and DFS (P=0.017 and P=0.012, respectively). Immunohistochemical expression was frequently detected for PDGFR-alpha (97.7%), PDGFR-beta (86.5%), and hepatocyte growth factor receptor (96.6%), whereas missense mutations were only identified in 2 cases both involving PDGFR-beta (exons 18 and 20). We conclude that de Perrot stratification of SFT is a reliable prognostic indicator and merits consideration in view of its suggestions for the management of these tumors in daily practice. p53 expression may represent a valid and easy-to-test prognostic factor significantly related to OS and DFS. Although mutations of the corresponding genes are rare events in SFT, PDGFR-alpha/beta, and hepatocyte growth factor receptor tyrosine kinases should be further investigated given the availability of specific inhibitory molecules which might provide useful and novel therapeutical approaches for SFT patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753943     DOI: 10.1097/PAS.0b013e31817a8a89

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  35 in total

1.  Solitary fibrous tumor of soft tissue: a case report and immunohistochemical study.

Authors:  Takashi Yuri; Sayaka Kanematsu; Yen-Chang Lei; Maki Kuwata; Masaharu Oishi; Airo Tsubura
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

Review 2.  Role of Immunohistochemistry in the Diagnosis of Solitary Fibrous Tumor, a Review.

Authors:  Bita Geramizadeh; Mahsa Marzban; Andrew Churg
Journal:  Iran J Pathol       Date:  2016

3.  Risk factor analysis for the recurrence of resected solitary fibrous tumours of the pleura: a 33-year experience and proposal for a scoring system.

Authors:  Luis F Tapias; Mari Mino-Kenudson; Hang Lee; Cameron Wright; Henning A Gaissert; John C Wain; Douglas J Mathisen; Michael Lanuti
Journal:  Eur J Cardiothorac Surg       Date:  2012-12-11       Impact factor: 4.191

4.  Solitary pulmonary adenofibroma in a middle-aged man with bladder cancer.

Authors:  Mohammad Al-Amer; Yazan Abdeen; Hamid Shaaban; Carlisle Alderink
Journal:  Lung India       Date:  2017 Nov-Dec

5.  Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

Authors:  Gian P Dagrada; Rosalin D Spagnuolo; Valentina Mauro; Elena Tamborini; Luca Cesana; Alessandro Gronchi; Silvia Stacchiotti; Marco A Pierotti; Tiziana Negri; Silvana Pilotti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

6.  Clinical behavior of solitary fibrous tumor: a retrospective review of 30 patients.

Authors:  Mª A Vaz Salgado; M Soto; Mª E Reguero; G Muñoz; A Cabañero; I Gallego; S Resano; F Longo; A Madariaga; A Gomez; A Carrato
Journal:  Clin Transl Oncol       Date:  2016-09-07       Impact factor: 3.405

7.  A case of dedifferentiated solitary fibrous tumor of the thoracic cavity.

Authors:  Yoshio Masuda; Aiko Kurisaki-Arakawa; Kieko Hara; Atsushi Arakawa; Shiaki Oh; Kenji Suzuki; Takashi Yao; Tsuyoshi Saito
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 8.  [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Med Klin (Munich)       Date:  2009-10-25

9.  A case of dedifferentiated solitary fibrous tumor in the pelvis with TP53 mutation.

Authors:  Aiko Kurisaki-Arakawa; Keisuke Akaike; Kieko Hara; Atsushi Arakawa; Michiko Takahashi; Keiko Mitani; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2014-11       Impact factor: 4.064

Review 10.  Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update review on the Doege-Potter syndrome.

Authors:  Ahmed Y Kalebi; Martin J Hale; Michelle L Wong; Tessa Hoffman; Jill Murray
Journal:  J Cardiothorac Surg       Date:  2009-08-18       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.